异动解读｜派格生物医药-B盘中上涨8.82%，派达康商业化持续催化估值修复

行情直击08-13

8月13日，派格生物医药-B盘中上涨8.82%，报6.725港元，成交额8605.05万港元。

消息面上，公司核心产品派达康近期在全国多家医疗机构及线上渠道开出首批商业化处方，触发第二笔约4900万港元里程碑付款，连同此前已收取的6100万港元，累计已收及触发权益金约1.1亿港元。此外，公司此前与Rani Therapeutics签署谅解备忘录推进口服制剂开发，与阿里健康、腾瑞制药签署战略合作打通线上线下商业化链路，维培那肽注射液亦已通过国家医保目录调整初步形式审查，多重利好叠加推动市场对公司商业化放量预期持续升温。

（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/1156396796?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-08-13 10:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156396796","market":"us","top_or_hot":-1,"title":"异动解读｜派格生物医药-B盘中上涨8.82%，派达康商业化持续催化估值修复","media":"行情直击","content":"<p><p>8月13日，派格生物医药-B盘中上涨8.82%，报6.725港元，成交额8605.05万港元。</p><p>消息面上，公司核心产品派达康近期在全国多家医疗机构及线上渠道开出首批商业化处方，触发第二笔约4900万港元里程碑付款，连同此前已收取的6100万港元，累计已收及触发权益金约1.1亿港元。此外，公司此前与Rani Therapeutics签署谅解备忘录推进口服制剂开发，与阿里健康、腾瑞制药签署战略合作打通线上线下商业化链路，维培那肽注射液亦已通过国家医保目录调整初步形式审查，多重利好叠加推动市场对公司商业化放量预期持续升温。</p><p>（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读｜派格生物医药-B盘中上涨8.82%，派达康商业化持续催化估值修复</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读｜派格生物医药-B盘中上涨8.82%，派达康商业化持续催化估值修复\n</h2>\n\n<h4 class=\"meta\">\n\n2026-08-13 10:54 北京时间&nbsp;&nbsp;&nbsp;<strong>行情直击</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>8月13日，派格生物医药-B盘中上涨8.82%，报6.725港元，成交额8605.05万港元。消息面上，公司核心产品派达康近期在全国多家医疗机构及线上渠道开出首批商业化处方，触发第二笔约4900万港元里程碑付款，连同此前已收取的6100万港元，累计已收及触发权益金约1.1亿港元。此外，公司此前与Rani Therapeutics签署谅解备忘录推进口服制剂开发，与阿里健康、腾瑞制药签署战略合作打通线...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02565","symbol_name":"派格生物医药-B","start_time":0,"source_url":"","article_id":"1156396796","we_media_id":"1059448697","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156396796","pubTimestamp":1786589641,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"行情直击","introduction":"个股异动一手消息解读","home_visible":1,"id":"1059448697","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"8月13日，派格生物医药-B盘中上涨8.82%，报6.725港元，成交额8605.05万港元。消息面上，公司核心产品派达康近期在全国多家医疗机构及线上渠道开出首批商业化处方，触发第二笔约4900万港元里程碑付款，连同此前已收取的6100万港元，累计已收及触发权益金约1.1亿港元。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02565":"派格生物医药-B"},"translate_title":"Interpretation of the change | Paige Biomedical-B rose by 8.82% in the intraday session, and the commercialization of Paidakang continued to catalyze valuation repair","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02565":1},"content_text":"8月13日，派格生物医药-B盘中上涨8.82%，报6.725港元，成交额8605.05万港元。消息面上，公司核心产品派达康近期在全国多家医疗机构及线上渠道开出首批商业化处方，触发第二笔约4900万港元里程碑付款，连同此前已收取的6100万港元，累计已收及触发权益金约1.1亿港元。此外，公司此前与Rani Therapeutics签署谅解备忘录推进口服制剂开发，与阿里健康、腾瑞制药签署战略合作打通线上线下商业化链路，维培那肽注射液亦已通过国家医保目录调整初步形式审查，多重利好叠加推动市场对公司商业化放量预期持续升温。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1156396796","isCrawlerRequest":true}